255 related articles for article (PubMed ID: 28763870)
1. [Effect of liraglutide in treatment of non-alcoholic fatty liver disease: mechanism of action and research advances].
Liu Y; Feng PP; Zhu W; Gong JP
Zhonghua Gan Zang Bing Za Zhi; 2017 Jun; 25(6):473-476. PubMed ID: 28763870
[TBL] [Abstract][Full Text] [Related]
2. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice.
Liu Q; Cai BY; Zhu LX; Xin X; Wang X; An ZM; Li S; Hu YY; Feng Q
Life Sci; 2020 Nov; 261():118457. PubMed ID: 32961235
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?
Athyros VG; Katsiki N; Karagiannis A
Curr Vasc Pharmacol; 2016; 14(6):494-497. PubMed ID: 27633289
[No Abstract] [Full Text] [Related]
5. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Zhang LY; Qu XN; Sun ZY; Zhang Y
Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):674-680. PubMed ID: 32113823
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
Khoo J; Hsiang J; Taneja R; Law NM; Ang TL
Diabetes Obes Metab; 2017 Dec; 19(12):1814-1817. PubMed ID: 28503750
[TBL] [Abstract][Full Text] [Related]
7. Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.
Ipsen DH; Rolin B; Rakipovski G; Skovsted GF; Madsen A; Kolstrup S; Schou-Pedersen AM; Skat-Rørdam J; Lykkesfeldt J; Tveden-Nyborg P
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):704-713. PubMed ID: 29953740
[TBL] [Abstract][Full Text] [Related]
8. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.
Bouchi R; Nakano Y; Fukuda T; Takeuchi T; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
Endocr J; 2017 Mar; 64(3):269-281. PubMed ID: 27916783
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of liraglutide on type 2 diabetic patients with nonalcoholic fatty liver disease.
Xu L; Wu C; Liu C; Ye Z; Huang J
Minerva Surg; 2023 Aug; 78(4):448-450. PubMed ID: 35088989
[No Abstract] [Full Text] [Related]
10. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway.
He Q; Sha S; Sun L; Zhang J; Dong M
Biochem Biophys Res Commun; 2016 Aug; 476(4):196-203. PubMed ID: 27208776
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study.
Rizvi AA; Patti AM; Giglio RV; Nikolic D; Amato A; Al-Busaidi N; Al-Rasadi K; Soresi M; Banach M; Montalto G; Rizzo M
Expert Opin Biol Ther; 2015; 15(10):1391-7. PubMed ID: 26195184
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy.
Zaitoon H; Lubetzky R; Amir AZ; Moran-Lev H; Sagi L; Yacobi-Bach M; Borger O; Chorna E; Lebenthal Y; Brener A
Acta Diabetol; 2023 Aug; 60(8):1099-1108. PubMed ID: 37160786
[TBL] [Abstract][Full Text] [Related]
14. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
Kalogirou MS; Patoulias D; Haidich AB; Akriviadis E; Sinakos E
Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101568. PubMed ID: 33309563
[TBL] [Abstract][Full Text] [Related]
15. Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.
Petit JM; Cercueil JP; Loffroy R; Denimal D; Bouillet B; Fourmont C; Chevallier O; Duvillard L; Vergès B
J Clin Endocrinol Metab; 2017 Feb; 102(2):407-415. PubMed ID: 27732328
[TBL] [Abstract][Full Text] [Related]
16. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide.
Kamm DR; Pyles KD; Sharpe MC; Healy LN; Colca JR; McCommis KS
J Biol Chem; 2021; 296():100807. PubMed ID: 34022222
[TBL] [Abstract][Full Text] [Related]
17. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics.
Jacobsen LV; Flint A; Olsen AK; Ingwersen SH
Clin Pharmacokinet; 2016 Jun; 55(6):657-72. PubMed ID: 26597252
[TBL] [Abstract][Full Text] [Related]
18. [Effects of antidiabetic medications on metabolic-associated fatty liver disease].
Scheen AJ
Rev Med Suisse; 2023 Aug; 19(838):1498-1502. PubMed ID: 37610193
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Clinical Value of Liraglutide for Treatment of Diabetes Mellitus Complicated by Non-Alcoholic Fatty Liver Disease.
Zhang Z; Qi Y; Kong W; Jin Q; Wang X; Dong Y; Wang Y; Li H
Med Sci Monit; 2018 Oct; 24():7399-7404. PubMed ID: 30325900
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological management of nonalcoholic fatty liver disease.
Barb D; Portillo-Sanchez P; Cusi K
Metabolism; 2016 Aug; 65(8):1183-95. PubMed ID: 27301803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
